Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Cancer Immunotherapy Webinar on September 12: Register Now
Posted on August 25th, 2017 by Patricia Morgan in Pharma R&D
After decades of being treated with a fairly typical combination of surgery and therapies, cancer is now being met with exciting new treatments that are more targeted and often less hard on the patient. Advanced technologies and techniques have been leading the way in these developments, providing greater insights into different kinds of cancers and how they uniquely affect individuals. The more scientists and researchers learn about cancer, the better equipped they are to find effective ways to fight it.
Immunotherapy is becoming one of the great new success stories in the treatment of cancer. Unlike the more traditional chemotherapy, which uses drugs to kill cancer cells, immune therapies actually utilize the patient’s own immune system to fight the disease. But is cancer immunotherapy developing at the pace that it should be, or are there particular challenges keeping this promising area from advancing?
On September 12, 2017, Elsevier is sponsoring an educational webinar titled Identifying Bottlenecks Associated with Cancer Immunotherapy Discovery and Development, featuring guest speakers Rakesh Dixit, Ph.D. (Vice President, Research & Development, and Global Head, Biologics Safety Assessment, MedImmune) and James Smothers, Ph.D. (Vice President, DPU Head, Immuno-Oncology & Combinations DPU, GlaxoSmithKline). In discussing a variety of issues regarding immune-oncology therapies, they will offer their insights on biology-related issues, safety concerns, and emerging methods that are critically important in developing these new therapies.
Whether you’re the director of an early discovery group at a pharma company, a manager overseeing clinical development in a university setting, or a scientist doing groundbreaking work at a small biotech firm, if you have an interest in immune therapies then you are sure to find this webinar enlightening. Expect to learn more about how disease biology can help the target selection process, better understand how adverse reactions to immune therapies can be avoided, and what is driving innovation in immunotherapy.
To join this webinar, you can register online here.
WHAT: Identifying Bottlenecks Associated with Cancer Immunotherapy Discovery and Development
WHEN: September 12, 2017 from 11AM to 12:30PM (EST)
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Product Marketing Manager
- Cancer-killing combo: Viagra and the flu vaccine
- As The Hive Evolves, More Companies Prepare to Join the Program
- Extreme Makeover: Clinical Trials Edition
- Seeking Other Perspectives to Tease Out New Innovations
- Myelo Therapeutics Takes on Unmet Needs in Cancer